Literature DB >> 19646406

Codon stabilization analysis of the "248" temperature sensitive mutation for increased phenotypic stability of respiratory syncytial virus vaccine candidates.

Cindy Luongo1, Lijuan Yang, Christine C Winter, Kirsten M Spann, Brian R Murphy, Peter L Collins, Ursula J Buchholz.   

Abstract

Human respiratory syncytial virus (RSV) is the most important viral agent of serious pediatric respiratory tract illness worldwide. Presently, the most promising vaccine candidate is a live, attenuated, cDNA-derived virus, RSV rA2cp248/404/1030DeltaSH, whose attenuation phenotype is based in large part on a series of point mutations including a glutamine to leucine (Q to L) substitution at amino acid residue 831 of the polymerase protein L, a mutation originally called "248". This mutation specifies both a temperature sensitive (ts) and attenuation phenotype. Reversion of this mutation from leucine back to glutamine was detected in some samples in clinical phase 1 trials. To identify the most genetically stable "attenuating" codon at this position to be included in a more stable RSV vaccine, we sought to create and evaluate recombinant RSVs representing all 20 possible amino acid assignments at this position, as well as small insertions and deletions. The recoverable viruses constituted a panel representing 18 different amino acid assignments, and were evaluated for temperature sensitivity in vitro and attenuation in mice. The original leucine mutation was found to be the most attenuating, followed only by phenylalanine. The paucity of highly attenuating assignments limited the possibility of increasing genetic stability. Indeed, it was not possible to find a leucine or phenylalanine codon requiring more than a single nucleotide change to yield a "non-attenuating" codon, as is necessary for the stabilization strategy. Nonetheless, serial passage of the six possible leucine codons in vitro at increasing temperatures revealed differences, with slower reversion to non-attenuated phenotypes for a subset of codons. Thus, it should be possible to modestly increase the phenotypic stability of the rA2cp248/404/1030DeltaSH vaccine virus by codon modification at the locus of the 248 mutation. In addition to characterizing the phenotypes associated with a particular locus in the RSV L protein, this manuscript provides insight into the problem of the instability of point mutations and the limitations of strategies to stabilize them.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19646406      PMCID: PMC2754210          DOI: 10.1016/j.vaccine.2009.07.022

Source DB:  PubMed          Journal:  Vaccine        ISSN: 0264-410X            Impact factor:   3.641


  28 in total

1.  Codon substitution mutations at two positions in the L polymerase protein of human parainfluenza virus type 1 yield viruses with a spectrum of attenuation in vivo and increased phenotypic stability in vitro.

Authors:  Josephine M McAuliffe; Sonja R Surman; Jason T Newman; Jeffrey M Riggs; Peter L Collins; Brian R Murphy; Mario H Skiadopoulos
Journal:  J Virol       Date:  2004-02       Impact factor: 5.103

2.  Granulocyte-macrophage colony-stimulating factor expressed by recombinant respiratory syncytial virus attenuates viral replication and increases the level of pulmonary antigen-presenting cells.

Authors:  A Bukreyev; I M Belyakov; J A Berzofsky; B R Murphy; P L Collins
Journal:  J Virol       Date:  2001-12       Impact factor: 5.103

3.  Neutralization epitopes of the F glycoprotein of respiratory syncytial virus: effect of mutation upon fusion function.

Authors:  J A Beeler; K van Wyke Coelingh
Journal:  J Virol       Date:  1989-07       Impact factor: 5.103

4.  Temperature-sensitive mutants of respiratory syncytial virus.

Authors:  M A Gharpure; P F Wright; R M Chanock
Journal:  J Virol       Date:  1969-04       Impact factor: 5.103

5.  Low-temperature-grown RS virus in adult volunteers.

Authors:  W T Friedewald; B R Forsyth; C B Smith; M A Gharpure; R M Chanock
Journal:  JAMA       Date:  1968-05-20       Impact factor: 56.272

6.  Bronchiolitis-associated hospitalizations among US children, 1980-1996.

Authors:  D K Shay; R C Holman; R D Newman; L L Liu; J W Stout; L J Anderson
Journal:  JAMA       Date:  1999-10-20       Impact factor: 56.272

7.  Evaluation of a temperature-sensitive mutant of respiratory syncytial virus in adults.

Authors:  P F Wright; J v Mills; R M Chanock
Journal:  J Infect Dis       Date:  1971-11       Impact factor: 5.226

8.  Evaluation of a live, cold-passaged, temperature-sensitive, respiratory syncytial virus vaccine candidate in infancy.

Authors:  P F Wright; R A Karron; R B Belshe; J Thompson; J E Crowe; T G Boyce; L L Halburnt; G W Reed; S S Whitehead; E L Anderson; A E Wittek; R Casey; M Eichelberger; B Thumar; V B Randolph; S A Udem; R M Chanock; B R Murphy
Journal:  J Infect Dis       Date:  2000-09-22       Impact factor: 5.226

9.  Administration of a highly attenuated, live respiratory syncytial virus vaccine to adults and children.

Authors:  P F Wright; R B Belshe; H W Kim; L P Van Voris; R M Chanock
Journal:  Infect Immun       Date:  1982-07       Impact factor: 3.441

10.  The burden of respiratory syncytial virus infection in young children.

Authors:  Caroline Breese Hall; Geoffrey A Weinberg; Marika K Iwane; Aaron K Blumkin; Kathryn M Edwards; Mary A Staat; Peggy Auinger; Marie R Griffin; Katherine A Poehling; Dean Erdman; Carlos G Grijalva; Yuwei Zhu; Peter Szilagyi
Journal:  N Engl J Med       Date:  2009-02-05       Impact factor: 91.245

View more
  15 in total

Review 1.  Respiratory syncytial virus vaccine development.

Authors:  Julia L Hurwitz
Journal:  Expert Rev Vaccines       Date:  2011-10       Impact factor: 5.217

2.  Respiratory syncytial virus modified by deletions of the NS2 gene and amino acid S1313 of the L polymerase protein is a temperature-sensitive, live-attenuated vaccine candidate that is phenotypically stable at physiological temperature.

Authors:  Cindy Luongo; Christine C Winter; Peter L Collins; Ursula J Buchholz
Journal:  J Virol       Date:  2012-12-12       Impact factor: 5.103

Review 3.  Progress in understanding and controlling respiratory syncytial virus: still crazy after all these years.

Authors:  Peter L Collins; José A Melero
Journal:  Virus Res       Date:  2011-09-22       Impact factor: 3.303

4.  Responses against a subdominant CD8+ T cell epitope protect against immunopathology caused by a dominant epitope.

Authors:  Tracy J Ruckwardt; Cindy Luongo; Allison M W Malloy; Jie Liu; Man Chen; Peter L Collins; Barney S Graham
Journal:  J Immunol       Date:  2010-09-10       Impact factor: 5.422

5.  Live Respiratory Syncytial Virus (RSV) Vaccine Candidate Containing Stabilized Temperature-Sensitivity Mutations Is Highly Attenuated in RSV-Seronegative Infants and Children.

Authors:  Ursula J Buchholz; Coleen K Cunningham; Petronella Muresan; Devasena Gnanashanmugam; Paul Sato; George K Siberry; Vivian Rexroad; Megan Valentine; Charlotte Perlowski; Elizabeth Schappell; Bhagvinji Thumar; Cindy Luongo; Emily Barr; Mariam Aziz; Ram Yogev; Stephen A Spector; Peter L Collins; Elizabeth J McFarland; Ruth A Karron
Journal:  J Infect Dis       Date:  2018-04-11       Impact factor: 5.226

6.  Live-attenuated respiratory syncytial virus vaccines.

Authors:  Ruth A Karron; Ursula J Buchholz; Peter L Collins
Journal:  Curr Top Microbiol Immunol       Date:  2013       Impact factor: 4.291

7.  Increased genetic and phenotypic stability of a promising live-attenuated respiratory syncytial virus vaccine candidate by reverse genetics.

Authors:  Cindy Luongo; Christine C Winter; Peter L Collins; Ursula J Buchholz
Journal:  J Virol       Date:  2012-07-25       Impact factor: 5.103

8.  A comprehensive proteomic view of responses of A549 type II alveolar epithelial cells to human respiratory syncytial virus infection.

Authors:  Keyur A Dave; Emma L Norris; Alexander A Bukreyev; Madeleine J Headlam; Ursula J Buchholz; Toshna Singh; Peter L Collins; Jeffrey J Gorman
Journal:  Mol Cell Proteomics       Date:  2014-08-08       Impact factor: 5.911

Review 9.  Sendai virus as a backbone for vaccines against RSV and other human paramyxoviruses.

Authors:  Charles J Russell; Julia L Hurwitz
Journal:  Expert Rev Vaccines       Date:  2015-12-09       Impact factor: 5.217

Review 10.  The immunogenicity and safety of respiratory syncytial virus vaccines in development: A systematic review.

Authors:  Jing Shan; Philip N Britton; Catherine L King; Robert Booy
Journal:  Influenza Other Respir Viruses       Date:  2021-03-25       Impact factor: 4.380

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.